Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy. A Double Blind Placebo- Controlled Cross-over Study in Subjects With the Metabolic Syndrome

NCT00405015 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT00405015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00405015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy. A Double Blind Placebo- Controlled Cross-over Study in Subjects With the Metabolic Syndrome
Lead sponsor
Radboud University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
October 31, 2008
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemia-reperfusion injury, the metabolic syndrome